SZNH(SH:600736)2022-10-28 16:00Financial Performance - The company's operating revenue for Q3 2022 was ¥1,157,742,862.70, a decrease of 66.97% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2022 was ¥40,126,963.75, down 73.10% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥52,994,989.14, a decrease of 52.62% compared to the same period last year[4] - The basic earnings per share for Q3 2022 was ¥0.03, a decline of 76.92% year-on-year[5] - In Q3 2022, the company reported a net profit of ¥277,228,425.58, a decrease of 18.1% compared to ¥338,703,146.14 in Q3 2021[22] - Net profit for the first three quarters of 2022 was ¥228.42 million, down 32.0% from ¥335.52 million in the same period of 2021[31] - Operating income for the first nine months of 2022 was ¥244.33 million, a decrease of 29.8% compared to ¥347.48 million in 2021[31] Assets and Liabilities - The total assets at the end of the reporting period were ¥62,957,139,121.96, an increase of 2.26% from the end of the previous year[5] - The total assets as of September 30, 2022, amounted to RMB 62,957,139,121.96, compared to RMB 61,567,222,488.04 at the end of the previous period, indicating a growth of 2.25%[18] - Total assets increased to ¥30.28 billion in Q3 2022, up from ¥25.20 billion in Q3 2021, representing a growth of 20.4%[29] - Total liabilities increased to RMB 47,314,143,626.31 from RMB 45,999,970,681.50, representing a rise of 2.85%[19] - Total liabilities reached ¥23.49 billion, up from ¥18.68 billion, indicating a rise of 25.0%[30] Cash Flow - The cash flow from operating activities for the year-to-date was -¥3,698,764,964.47, a decrease of 405.74% compared to the same period last year[4] - The company experienced a net cash outflow from operating activities of ¥3,698,764,964.47 in the first nine months of 2022, compared to a net inflow of ¥1,209,775,134.18 in the same period of 2021[25] - Cash flow from operating activities generated ¥1.04 billion, down from ¥1.65 billion in the previous year, a decline of 37.0%[33] - Investment activities generated cash inflow of ¥5.04 billion, significantly lower than ¥11.36 billion in the same period last year, a decrease of 55.7%[33] - The net cash flow from investing activities was -4,098,389,921.95 CNY, compared to -2,904,903,634.48 CNY in the previous period[34] - The total cash inflow from financing activities was 14,642,470,000.00 CNY, an increase from 10,274,600,000.00 CNY year-over-year[34] - The net cash flow from financing activities was 3,013,190,169.78 CNY, up from 715,181,682.36 CNY in the previous period[34] Shareholder Equity - The equity attributable to shareholders of the listed company was ¥9,409,283,186.97, up 2.66% from the end of the previous year[5] - The company reported a total equity of ¥6.79 billion, an increase from ¥6.52 billion, reflecting a growth of 4.1%[30] Investment Activities - The company acquired a 30.90% stake in a medical device company for RMB 242.71 million and increased its shareholding to 51.37% through a cash capital increase of RMB 330 million[13] - The company invested RMB 50 million in a private placement of Linweina and RMB 5 million in a project of Aiyidongbao during the year[13] - The company's long-term equity investments rose to RMB 3,120,978,577.81 from RMB 2,944,146,907.03, an increase of 6%[17] Financial Expenses - The company’s financial expenses increased to ¥412,008,195.84 in Q3 2022, up from ¥297,570,932.47 in Q3 2021, reflecting higher borrowing costs[22] - The company’s financial expenses increased to ¥574.69 million, up from ¥382.04 million, representing a rise of 50.4%[31] Research and Development - The company reported a significant increase in research and development expenses, totaling ¥22,617,859.57 in Q3 2022, compared to ¥17,134,153.63 in Q3 2021, indicating a focus on innovation[22] Cash and Cash Equivalents - The company's cash and cash equivalents decreased to RMB 5,547,862,696.19 from RMB 6,399,190,614.21, a decline of 13.4%[17] - Cash and cash equivalents at the end of Q3 2022 stood at ¥4,357,163,748.74, a decrease from ¥3,366,266,321.43 at the end of Q3 2021[25] - Cash and cash equivalents at the end of the period totaled 2,421,744,153.80 CNY, compared to 1,780,231,356.42 CNY at the end of the previous period[34] - The net increase in cash and cash equivalents was -44,386,119.61 CNY, compared to -540,980,182.04 CNY in the previous period[34] Other Financial Information - The company experienced a significant decline in revenue and profit due to the cyclical impact of real estate project handovers[9] - The total number of ordinary shareholders at the end of the reporting period was 67,731[10] - The company did not apply new accounting standards or interpretations for the year 2022[34]